Dis-Chem Pharmacies Balance Sheet Health
Financial Health criteria checks 6/6
Dis-Chem Pharmacies has a total shareholder equity of ZAR4.9B and total debt of ZAR2.3B, which brings its debt-to-equity ratio to 47.9%. Its total assets and total liabilities are ZAR18.2B and ZAR13.3B respectively. Dis-Chem Pharmacies's EBIT is ZAR1.9B making its interest coverage ratio 4. It has cash and short-term investments of ZAR824.4M.
Key information
47.9%
Debt to equity ratio
R2.33b
Debt
| Interest coverage ratio | 4x |
| Cash | R824.41m |
| Equity | R4.86b |
| Total liabilities | R13.35b |
| Total assets | R18.20b |
Recent financial health updates
Is Dis-Chem Pharmacies (JSE:DCP) Using Too Much Debt?
Nov 27
These 4 Measures Indicate That Dis-Chem Pharmacies (JSE:DCP) Is Using Debt Reasonably Well
Aug 21Dis-Chem Pharmacies (JSE:DCP) Seems To Use Debt Quite Sensibly
Feb 26Here's Why Dis-Chem Pharmacies (JSE:DCP) Can Manage Its Debt Responsibly
Aug 16Dis-Chem Pharmacies (JSE:DCP) Has A Pretty Healthy Balance Sheet
Jun 08Is Dis-Chem Pharmacies (JSE:DCP) A Risky Investment?
Feb 23Recent updates
Is Dis-Chem Pharmacies (JSE:DCP) Using Too Much Debt?
Nov 27Shareholders Are Optimistic That Dis-Chem Pharmacies (JSE:DCP) Will Multiply In Value
Nov 10These 4 Measures Indicate That Dis-Chem Pharmacies (JSE:DCP) Is Using Debt Reasonably Well
Aug 21Shareholders Should Be Pleased With Dis-Chem Pharmacies Limited's (JSE:DCP) Price
Jun 06Dis-Chem Pharmacies (JSE:DCP) Will Be Hoping To Turn Its Returns On Capital Around
Apr 17Dis-Chem Pharmacies (JSE:DCP) Seems To Use Debt Quite Sensibly
Feb 26Dis-Chem Pharmacies (JSE:DCP) Might Be Having Difficulty Using Its Capital Effectively
Dec 30If EPS Growth Is Important To You, Dis-Chem Pharmacies (JSE:DCP) Presents An Opportunity
Sep 07Here's Why Dis-Chem Pharmacies (JSE:DCP) Can Manage Its Debt Responsibly
Aug 16Dis-Chem Pharmacies (JSE:DCP) Will Want To Turn Around Its Return Trends
Jul 31Is Now The Time To Put Dis-Chem Pharmacies (JSE:DCP) On Your Watchlist?
May 09There Are Reasons To Feel Uneasy About Dis-Chem Pharmacies' (JSE:DCP) Returns On Capital
Mar 29Is Now The Time To Put Dis-Chem Pharmacies (JSE:DCP) On Your Watchlist?
Jan 14Returns On Capital At Dis-Chem Pharmacies (JSE:DCP) Paint A Concerning Picture
Nov 04Dis-Chem Pharmacies Limited (JSE:DCP) Shares Could Be 24% Below Their Intrinsic Value Estimate
Oct 04We Ran A Stock Scan For Earnings Growth And Dis-Chem Pharmacies (JSE:DCP) Passed With Ease
Sep 01Some Investors May Be Worried About Dis-Chem Pharmacies' (JSE:DCP) Returns On Capital
Jul 04A Look At The Fair Value Of Dis-Chem Pharmacies Limited (JSE:DCP)
Jun 21Dis-Chem Pharmacies (JSE:DCP) Has A Pretty Healthy Balance Sheet
Jun 08The Dis-Chem Pharmacies Limited (JSE:DCP) Yearly Results Are Out And Analysts Have Published New Forecasts
May 25Is Dis-Chem Pharmacies (JSE:DCP) A Risky Investment?
Feb 23Dis-Chem Pharmacies Limited's (JSE:DCP) Price In Tune With Earnings
Feb 08I Ran A Stock Scan For Earnings Growth And Dis-Chem Pharmacies (JSE:DCP) Passed With Ease
Dec 13Dis-Chem Pharmacies' (JSE:DCP) Strong Earnings Are Of Good Quality
Nov 09Financial Position Analysis
Short Term Liabilities: DCP's short term assets (ZAR11.4B) exceed its short term liabilities (ZAR9.6B).
Long Term Liabilities: DCP's short term assets (ZAR11.4B) exceed its long term liabilities (ZAR3.7B).
Debt to Equity History and Analysis
Debt Level: DCP's net debt to equity ratio (30.9%) is considered satisfactory.
Reducing Debt: DCP's debt to equity ratio has reduced from 82.2% to 47.9% over the past 5 years.
Debt Coverage: DCP's debt is well covered by operating cash flow (82.6%).
Interest Coverage: DCP's interest payments on its debt are well covered by EBIT (4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 18:06 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/02/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dis-Chem Pharmacies Limited is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Dias | Arqaam Capital Research Offshore S.A.L. |
| Michael de Nobrega | Avior Capital Markets |
| Paul Henri Steegers | BofA Global Research |